Biocon Gains EU Approval for Pertuzumab Biosimilar in Breast Cancer
Biocon secures EMA marketing authorisation for a pertuzumab biosimilar covering HER2-positive breast cancer across multiple disease stages in the EU.


Biocon's European Marketing Authorisation for its pertuzumab biosimilar sets a live reference point for biosimilar manufacturers working through EMA comparability requirements for HER2-targeted monoclonal antibodies, a regulatory pathway that demands rigorous analytical, clinical, and GMP-aligned manufacturing evidence before a dossier reaches the Committee for Medicinal Products for Human Use.
The approval covers treatment of HER2-positive breast cancer across multiple disease stages within the European Union, positioning the biosimilar to compete directly with Roche's Perjeta in a market where oncology biologics face sustained pricing pressure from payer bodies. For QA directors and regulatory affairs leads at biosimilar manufacturers, the authorisation signals that the EMA's evidentiary bar for a complex, co-administered monoclonal antibody, pertuzumab is typically given alongside trastuzumab and chemotherapy, can be cleared with a well-structured comparability package.
The EMA biosimilar pathway requires demonstration of physicochemical and functional similarity, followed by clinical pharmacokinetic and, where necessary, efficacy and safety data. For HER2-targeted biologics specifically, the analytical comparability exercise must account for the antibody's mechanism of action at the HER2 dimerisation domain, adding complexity to the structural characterisation workload. Manufacturing sites supplying the EU market must also satisfy EU GMP standards, with batch release subject to Official Medicines Control Laboratory testing for biological products.
Biocon has built a biosimilar portfolio across oncology and immunology, with prior approvals in both the EU and US markets providing an established regulatory track record. The pertuzumab authorisation extends that portfolio into a combination-regimen oncology setting, where post-approval pharmacovigilance obligations and risk management plans will govern the product's lifecycle under EMA's ICH E2E-aligned pharmacovigilance framework.
Plant heads and supply-chain leads preparing EU biosimilar submissions should note that the pertuzumab approval reinforces the EMA's consistent application of its biosimilar guideline, particularly around the stepwise comparability approach and the sufficiency of PK bridging data to support full indication extrapolation across HER2-positive disease stages.
The next measurable checkpoint for Biocon will be the commercial launch timeline and the outcome of national pricing and reimbursement negotiations across key EU member states, which will determine the biosimilar's actual market penetration against the reference product.
Source: Media4Growth via Indian Pharma Post, 18 November 2026.

Reporting on the science, business and regulation shaping the pharmaceutical industry.



Discussion